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Context. Patients with advanced cancer commonly suffer from both distressing symptoms and cognitive impairment, but
the effect of cognitive impairment on the reliability and validity of symptom self-report is unknown.
Objectives. To evaluate the reliability and validity of symptom self-report in cancer outpatients with and without mild to
moderate cognitive impairment.
Methods. This was an analysis of the longitudinal EuropeanPalliativeCareCancer Symptom study of adults with incurable cancer
in specializedpalliative care (30 centers across 12 countries). Patients who couldnot complywith the study because of severe cognitive
impairmentwere excluded.Cognitive status on theMini-Mental StateExamination short versionandnine symptoms (pain, tiredness,
drowsiness, nausea, appetite, breathlessness, depression, anxiety, and well-being) using the revised Edmonton SymptomAssessment
System were self-reported at baseline and one-month follow-up. Reliability was analyzed using intraclass correlation coefficients and
validity using regression of each symptom with health-related quality of life (HrQoL) measured with European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire Core 15 for Palliative Care.
Results. A total of 1047 patients were included: mean age of 62.9 years; 54.4% women; main cancer types were of digestive
organs (26.6%), breast (21.6%), and lungs (21.2%). Cognitive impairment was present in 181 (17.3%) at baseline and
associated with worse self-reported tiredness, drowsiness, appetite, and depression. Reliability (intraclass correlation
coefficient) and validity (associations with HrQoL) were similar between people with/without cognitive impairment across the
nine symptoms, except breathlessness, which showed a weaker relation to HrQoL in patients with cognitive impairment.
Findings were robust in sensitivity analyses and after controlling for potential confounders.
Conclusion. In advanced cancer, self-report of nine major symptoms was reliable and valid also in people with mild-to-
moderate cognitive impairment.M. P. E. and S. P. contributed equally to the article as shared
first authors.
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In this longitudinal cohort study of 1047 cancer out-
patients, mild-to-moderate cognitive impairment was
common (17%). Self-report of nine major symptoms
was reliable and valid also in patients with mild-to-
moderate cognitive impairment, but proxy report
may be needed for some patients with advanced
cancer who are unable to self-report.
Introduction
Symptom assessment is essential for clinical evalua-
tion and care in people with cancer for improved
health-related quality of life (HrQoL) and reduced
patient suffering. Symptoms should be assessed using
validated instruments, which have established
reliability and enable valid interpretation and compar-
ison, such as a 0e10 Numerical Rating Scale (NRS).1,2
Although important throughout the disease trajectory,
symptom assessment becomes even more important in
advanced cancer with worsening symptom burden. At
this stage, self-reported symptom measures might be
influenced by clinical factors including cognitive
impairment.
Cognitive impairment is common in cancer,
affecting up to 30% before chemotherapy3 and up
to 75% during or after chemotherapy.4 The impair-
ment is often global, affecting, for example, memory,
attention, and executive functions.5 The cause is
multifactorial and can be related to cancer therapy
(especially chemotherapy),6 pain and other symp-
toms,7 medications, the cancer itself,4 or secondary
symptoms, such as insomnia, pain, fatigue, and
depression.8,9 Many cancer-related symptoms, such as
pain, are underreported (if not actively assessed) in
cognitively impaired compared with cognitively unim-
paired individuals.3 This leads to poorer pain manage-
ment among cognitively impaired3,10e13 and
highlights the need to actively administer and
thoroughly evaluate self-reported symptom scales in
vulnerable patients to assess and document symptoms
and optimize treatment.
However, cognitive impairment may affect the abil-
ity to self-assess symptoms on, for example, the NRS
measures. Because these are popular tools both in
clinical settings and drug trials of patients with cancer,
incorrect self-reporting, on, for example, the NRS,could result in poorer symptom management and
affect trial outcomes. There are previous studies that
evaluated the properties of the NRS to assess pain in
elderly and cognitive impaired patients;14e19 however,
to our knowledge, the systematic assessment of the
effect of cognitive impairment on symptom scoring us-
ing an NRS in patients with cancer is unknown. An
issue when evaluating the accuracy of symptom report
is the lack of an objective gold standard for the expe-
rienced sensations other than self-report. As a way to
address this issue, studies have examined the effect
of cognition on the symptom scores’ test-retest
reliability,14,16,20 which informs on the amount of
variability or random error. By comparing with the
reliability in people without cognitive impairment,
one can evaluate whether people with cognitive
impairment self-rate in a less reliable and more vary-
ing manner. In addition, the association between the
symptom scores with other relevant scales such as
HrQoL (concurrent validity) can be evaluated, which
informs on the systematic error, or to what degree
the measure assesses the right thing and in a similar
way between groups.21,22
The aims of the present study were to examine if in-
dividuals with advanced cancer and cognitive impair-
ment had lower test-retest reliability in self-reported
measures of pain, tiredness, drowsiness, nausea, lack
of appetite, breathlessness, depression, anxiety, and
well-being; poorer association between these ratings
and global HrQoL; and higher rates of missing data,
compared with patients with cancer without cognitive
impairment.
Material and Methods
Study Design and Population
This was a prospective longitudinal analysis of the
European Palliative Care Cancer Symptom (EPCCS)
study, the largest prospective longitudinal study to
date of adults with incurable cancer enrolled in a palli-
ative care program, with data from 30 palliative care
centers across Europe, Australia, and Canada (12
countries).23 The study was performed according to
the Declaration of Helsinki and was registered in the
ClinicalTrials.gov database (NCT01362816). This
article is reported in accordance with the STrength-
ening the Reporting of OBservational studies in
Epidemiology framework for observational studies.24
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able data on cognition (Mini-Mental State Examina-
tion [MMSE] short version) and all nine symptom
scores at baseline. Exclusion criteria for the EPCCS
study included inability to participate because of psy-
chotic disorders, severe cognitive impairment, or lan-
guage problems.23
Assessments
We included data from the first clinical assessment
(baseline) and the first follow-up appointment after
approximately four weeks.23 Data from subsequent
appointments were not included because of high rates
of missing data. At baseline, assessments included
demographics; time from cancer diagnosis; diagnosed
comorbidities (chronic obstructive pulmonary disease
[COPD], heart disease, liver disease, and renal disease);
marital status; and highest education. At each study
assessment, data were collected on height and weight;
change in weight during the previous two and six
months; cancer diagnosis, cancer stage, metastases to
bone, central nervous system (CNS), lung, lymph no-
des, other; medications, including glucocorticoids, opi-
oids, other analgesics, and sedatives/anxiolytics;
Karnofsky Performance Scale;25 severity of nine symp-
toms (the revised Edmonton Symptom Assessment Sys-
tem; ESAS-r);26 and whether data were patient or proxy
reported. Data on medication preparation or doses
were unavailable. Cognitive status was assessed using
the four-item short version of the MMSE.27,28 In this
short version, the following MMSE items are included:
1) recalling present year (0e1 p), 2) recalling present
date (0e1 p), 3) backward spelling of WORLD (0e5
p; 1 p for each correct letter), and 4) copying of two in-
terlocking pentagons (0e1 p). This instrument screens
for cognitive impairment in memory, attention/execu-
tive, and visuospatial domains. Cognitive impairment
was defined as 0 p for year (i.e., incorrect year) or <3
p on spelling WORLD backward or 0 p on pentagon
copying at baseline (i.e., incorrect pentagon
copying).29 Date was not included in the definition of
cognitive impairment because even cognitively unim-
paired individuals can have difficulties recalling the
exact present date. Severity of symptoms was scored
on anNRSbetween0 (no) and10 (worst possible) using
the wording of the ESAS-r: ‘‘Please circle the number
that best describes how you feel now.’’26 HrQoL was as-
sessed using the European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire
Core 15 for Palliative Care questionnaire.30
Statistical Analyses
Baseline patient characteristics were summarized
using mean with SD and median with range or inter-
quartile range for continuous variables with normal
and skewed distribution, respectively. Categoricalvariables were expressed as frequencies and percent-
ages. Data from the first two assessments were used
because of high rates of patients with missing data at
the third assessment on symptoms or cognition
(n ¼ 716; 45.4%). Only data by patient self-report
were included in the analyses. ESAS-r symptom scores,
their reliability, and concurrent validity (association
with HrQoL) were compared between patients with
and without cognitive impairment. Reliability between
baseline and the second visit was analyzed using the
intraclass correlation coefficient using multilevel
linear regression, accounting for repeated measure-
ments. Associations (concurrent validity) for symp-
toms with HrQoL at baseline were analyzed using
linear regression. Analyses were adjusted for the
potential confounders: age, sex, level of education,
opioid treatment, and treatment with sedatives/anxio-
lytics. Whether the associations differed by cognitive
impairment was tested using an interaction term in
the fully adjusted model. P-values of interactions
were calculated using likelihood ratio test.
A sensitivity analysis was conducted, where all ana-
lyses were compared between patients who had cogni-
tive impairment at both baseline and follow-up and
patients who did not have cognitive impairment at
any of these assessments. The group with cognitive
impairment at both assessments was relatively small
(n ¼ 52); it was not the primary study population
but was analyzed as a sensitivity analyses.
Estimates were reported with 95% CIs. Statistical
significance was defined as two-sided P-value <0.05.
Statistical analyses were conducted using the software
packages Stata, Version 14.2 (StataCorp LP, College
Station, TX).Results
Patient Characteristics
A total of 1047 patients were included in the analysis
after excluding patients with missing baseline data on
cognition (n ¼ 56) or missing ESAS-r symptom scores
(n ¼ 107) and patients with data reported by proxy
(n ¼ 529). The included 1047 patients had a mean
age of 62.9 (SD 12.1) years, 54.4% were women, and
the most common cancer types were cancer of the
digestive organs (26.6%), breast cancer (21.6%), and
lung cancer (21.2%) (Table 1). Most patients were
ambulatory (not bedbound), with 69.7% having a
functional status on Karnofsky Performance Scale of
70 or higher.
Cognitive Impairment and Follow-Up
Cognitive impairment was present in 181 (17.3%)
patients at baseline. The distributions of MMSE scores
stratified by cognitive status are shown in Appendix
Table 1





Impairment, n (%) P
N 181 866
MMSE short version total score;
median (IQR)
5.00 (4.00, 7.00) 8.00 (8.00, 8.00) <0.001
Age; mean (SD) 68.55 (11.52) 61.71 (11.87) <0.001
Women 83 (45.9) 487 (56.2) 0.011
Highest completed education <0.001
Less than nine years of
schooling
95 (52.5) 194 (22.4)
10e12 yrs of schooling 65 (35.9) 394 (45.5)
College or university less than
four years
10 (5.5) 169 (19.5)
College or university four years
and greater
11 (6.1) 102 (11.8)
Missing 0 (0.0) 7 (0.8)
Days since diagnosis; median
(IQR)
391 (195, 1114) 634 (246, 1627) 0.006
Principal cancer diagnosis 0.021
Cancer of the head 8 (4.4) 28 (3.2)
Cancer of the digestive organs 43 (23.8) 235 (27.1)
Cancer of the respiratory organs 45 (24.9) 177 (20.4)
Malignant bone tumors 0 (0.0) 8 (0.9)
Skin cancer incl. malignant
melanoma
3 (1.7) 18 (2.1)
Malignant connective and soft
tissue tumors
3 (1.7) 21 (2.4)
Breast cancer 23 (12.7) 203 (23.4)
Gynecological cancer 18 (9.9) 45 (5.2)
Cancer of the male genital
organs
13 (7.2) 56 (6.5)
Urinary cancer 8 (4.4) 30 (3.5)
Tumors of the CNS 4 (2.2) 6 (0.7)




4 (2.2) 8 (0.9)
Leukemias and lymphomas 7 (3.9) 24 (2.8)
Missing 1 (0.6) 3 (0.3)
Stage of nonsolid cancer 0.46
Localized 4 (2.2) 8 (0.9)
Disseminated 5 (2.8) 18 (2.1)
Stage of solid cancer
Localized 8 (4.8) 34 (4.2) 0.74
Metastatic 135 (76.7) 732 (86.3) 0.001
Metastasis to lung 51 (28.3) 256 (29.6) 0.74
Metastasis to liver 46 (25.6) 265 (30.6) 0.18
Metastasis to CNS 17 (9.4) 65 (7.5) 0.38
Metastasis to bone 66 (36.7) 356 (41.1) 0.27
COPD 14 (7.7) 79 (9.1) 0.55
Heart disease 68 (37.6) 212 (24.5) <0.001
Liver disease 10 (5.5) 20 (2.3) 0.018
Renal disease 7 (3.9) 28 (3.2) 0.67
Karnofsky Performance Status;
mean (SD)
63.28 (14.94) 72.94 (14.00) <0.001
Body mass index; mean (SD) 24.36 (5.00) 24.61 (4.93) 0.56
Oral corticosteroids 79 (43.6) 379 (43.8) 0.88
Opioids 118 (65.2) 479 (55.3) 0.005
Nonopioid analgesics 81 (44.8) 383 (44.2) 0.72
Sedatives/anxiolytics 71 (39.2) 209 (24.1) <0.001
Antidepressants 34 (18.8) 118 (13.6) 0.061
Follow-up visit with self-reported
data
86 (47.5) 590 (68.1) <0.001
MMSE ¼ Mini-Mental State Examination; IQR ¼ interquartile range; CNS ¼ central nervous system; COPD ¼ chronic obstructive pulmonary disease.
Data presented as frequency (%) or mean (SD) unless otherwise stated.
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cognitive impairment are shown in Table 1. The cogni-
tively impaired group had higher prevalence of men,lower level of education, lower functional status,
more recent cancer diagnosis, more often in treat-
ment with opioids, sedatives/anxiolytics and
Table 2







(N ¼ 866) P
Pain 2.30 (2.51) 2.07 (2.38) 0.25
Tiredness 4.77 (3.13) 3.98 (2.79) <0.001
Drowsiness 3.27 (2.88) 2.82 (2.74) 0.048
Nausea 0.76 (1.79) 1.04 (1.97) 0.081
Appetite 3.45 (3.41) 2.58 (2.97) <0.001
Breathlessness 1.69 (2.29) 1.66 (2.34) 0.89
Depression 3.17 (3.00) 2.27 (2.76) <0.001
Anxiety 2.46 (2.71) 2.21 (2.58) 0.24
Well-being 3.70 (2.64) 3.39 (2.67) 0.15
Data presented as mean (SD). P-values were calculated using t-tests.
Table 3








Pain 0.51 (0.41e0.62) 0.53 (0.49e0.57)
Tiredness 0.53 (0.43e0.63) 0.54 (0.51e0.58)
Drowsiness 0.50 (0.39e0.60) 0.51 (0.47e0.55)
Nausea 0.55 (0.45e0.65) 0.42 (0.37e0.46)
Appetite 0.56 (0.46e0.66) 0.50 (0.46e0.54)
Breathlessness 0.54 (0.44e0.64) 0.58 (0.54e0.62)
Depression 0.44 (0.33e0.55) 0.60 (0.56e0.63)
Anxiety 0.40 (0.29e0.52) 0.56 (0.52e0.60)
Well-being 0.59 (0.49e0.68) 0.52 (0.48e0.56)
ICC ¼ intraclass correlation coefficient.
Reliability of symptom scores (on the revised Edmonton Symptom Assessment
System) was measured using the ICC based on the baseline and first follow-up
visit. Estimates are presented with 95% CIs.
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cognitive impairment. Characteristics were similar be-
tween groups in terms of cancer types (except slightly
less breast cancer among cognitively impaired), cancer
stage, rate of CNS cancer, and CNS metastases (9.4%
vs. 7.5% in patients without cognitive impairment).
The follow-up assessment was attended by 810
(77.4%) patients after a median of 29 days (interquar-
tile range 27e35; range 14e162). Fewer patients with
cognitive impairment attended the follow-up assess-
ment (125 of 181 [69.1%] vs. 685 of 866 [79.1%];
P ¼ 0.003), and fewer of those attending follow-up
had self-reported data (86 of 125 [68.8%] vs. 590 of
685 [86.1%]; P < 0.001). Cognitive status (MMSE)
by self-report at follow-up was available for 47.5% of
patients with cognitive impairment at baseline,
compared with 68.1% of patients without baseline
cognitive impairment (Appendix Table 1). For
symptom data, patients with cognitive impairment at
baseline had higher rates of missing data at follow-
up, which was consistent across the different
symptoms (Appendix Table 2).Reliability of Symptom Ratings in Cognitively
Impaired and Unimpaired
Cognitive impairment was associated with worse self-
reported tiredness, drowsiness, appetite, and
perceived depression at baseline (Table 2). There
were no differences by cognitive status for levels of
pain, nausea, breathlessness, anxiety, or overall well-
being.
Reliability (variability between the baseline and the
follow-up assessment) was similar, with no consistent
systematic difference (similar estimates with overlap-
ping 95% CIs) between patients with and without
cognitive impairment overall across the nine symp-
toms (Table 3). There were trends of differences for
a few symptoms; patients with cognitive impairment
tended to have somewhat lower reliability for anxiety
and depression and slightly higher for nausea, but dif-
ferences were generally small.Cognition and Concurrent Validity of Symptoms With
HrQoL
The association of each symptom score with the
perceived overall HrQoL (European Organization
for Research and Treatment of Cancer Quality of
Life Questionnaire Core 15 for Palliative Care) was
compared between people with and without cognitive
impairment, as shown in Table 4. Associations were
adjusted for age, sex, level of education, and treat-
ment with opioids and sedatives/anxiolytics. Worse
symptom scores in both groups were associated with
worse HrQoL. There were no statistically significant
group differences in the associations between symp-
toms and HrQoL (interaction group  symptom
score), except for breathlessness where the association
between breathlessness and worse HrQoL was smaller
in patients with cognitive impairment (P ¼ 0.016 for
interaction; Table 4).Sensitivity Analyses
As cognitive status changed in some patients be-
tween baseline and follow-up, all analyses were also
conducted in patients with cognitive status defined
as the presence/absence of cognitive impairment
both at baseline and follow-up. Of 641 patients
included in this analysis, 52 (8.1%) had cognitive
impairment at both baseline and follow-up, and 589
(91.9%) did not have cognitive impairment at any of
the assessments. Symptom scores were overall similar
between groups (Appendix Table 3), with cognitive
impairment associated with worse scores for tiredness,
appetite, and depression but with lower levels of
nausea and breathlessness, which was not seen in the
main analysis of the larger patient cohort. Reliability
estimates showed lower precision (because of the
smaller sample size), but the pattern of estimates was
similar to the main analysis (Appendix Table 4). There
was no evidence of lower reliability in people with
Vol. 60 No. 2 August 2020 351Cognition and Symptom Rating in Cancer Outpatientscognitive impairment. Associations of symptoms with
HrQoL showed a similar pattern as in the main
analysis.
In addition, because of non-normality of symptom
scores, we ran all analyses using the logarithm instead
of raw symptom scores, which yielded similar findings.Discussion
In this large, multinational, prospective, and longi-
tudinal study of 1047 participants with advanced
cancer, we examined the relation between mild-to-
moderate cognitive impairment and the ability to
self-report a range of important symptoms: pain,
tiredness, drowsiness, nausea, lack of appetite, breath-
lessness, depression, anxiety, and overall well-being.
Compared with cognitively unimpaired, patients with
cognitive impairment had similar test-retest reliability
and similar associations with overall QoL for the symp-
tom scores. Patients with cognitive impairment had
more severe disease and were less likely to attend
follow-up and to self-report. The main finding is that
among people with cancer and cognitive impairment
who were able to self-report, symptom ratings were still
reliable and valid compared with people without
cognitive impairment.
This is the largest study, to our knowledge, that eval-
uates the relation between cognitive impairment and
symptom report and also the broadest study in terms
of the range of evaluated symptoms (nine items),
covering the major symptoms that affect people with
cancer. Most previous studies evaluated self-report of
pain and report that the ability seems intact in mild-
to-moderate cognitive impairment,16e19 in agreement
with the present study, and that self-assessed and staff-
assessed pain scores agree down to MMSE scores of 10
out of 30 points (severe cognitive impairment).Table






Coefficient 95% CI Coefficient
Pain 3.17 4.76 to 1.58 2.48
Tiredness 3.93 5.01 to 2.84 3.11
Drowsiness 3.45 4.72 to 2.18 2.50
Nausea 3.63 5.80 to 1.46 2.68
Appetite 2.51 3.60 to 1.43 3.02
Breathlessness 0.18 1.90 to 1.55 2.07
Depression 4.05 5.26 to 2.84 2.76
Anxiety 2.64 4.12 to 1.15 2.60
Well-being 5.03 6.31 to 3.75 3.93
Linear regression of the association for each symptom (assessed using the revised E
quality of life (HrQoL) measured using European Organization for Research and T
adjusted for age, sex, level of education, and treatment with opioids and anxiolyti
tested using likelihood ratio test. Higher HrQoL scores (outcome variable) reflect
Assessment System instrument; the predictors) reflect more severe symptoms. A ne
with worse HrQoL.Although the concurrent validity with other scales
seem to diminish in severe dementia,14 at least one
study has shown a high reliability (intraclass correla-
tion coefficient) between three self-reported pain
scales (0.88e0.98), reflected also in correlation with
observational pain ratings (r ¼ 0.25e0.63).15
In the present study, we found that worse symptom
scores were related to cognitive impairment for tired-
ness, drowsiness, appetite, and perceived depression,
which is in line with previous reports.31e33 Cognitive
status was, however, not associated with ratings for
any other symptoms, which is in agreement with previ-
ous studies on anxiety34,35 and pain.36 To the authors’
knowledge, there are no comparable studies on
cognition and reported breathlessness. Experimen-
tally induced acute breathlessness was reported to
affect cognitive control of locomotion in healthy
people.37 In COPD, cognitive impairment on the
MMSE was associated with having more severe symp-
toms and a larger difference between experienced
and recalled breathlessness (n ¼ 30).38 In contrast,
another study of 183 patients with COPD found
similar characteristics, symptoms, and QoL between
patients with and without cognitive impairment.39
In the present study, symptom scores had similar
associations with perceived HrQoL between patients
with and without cognitive impairment, except for
breathlessness, where a similar increase in the symp-
tom score (worse breathlessness) was associated with
a smaller reduction in HrQoL in patients with cogni-
tive impairment than in patients without cognitive
impairment. As this was the only statistically significant
difference, it should be interpreted with caution as it
not only might reflect a random fluctuation but also
could indicate that other things may be more influen-
tial on HrQoL in cognitive impairment.
A limitation of the present study is that the definition
of cognitive impairment was based on a brief cognitive4
lobal Quality of Life by Cognitive Status
Without Cognitive
mpairment
Difference in Association (Interaction)
Between the Groups
95% CI P
3.21 to 1.76 0.56
3.67 to 2.54 0.29
3.10 to 1.90 0.71
3.50 to 1.86 0.41
3.55 to 2.48 0.40
2.77 to 1.38 0.016
3.36 to 2.17 0.067
3.24 to 1.97 0.94
4.51 to 3.35 0.190
dmonton Symptom Assessment System instrument) with global health-related
reatment of Cancer Quality of Life Questionnaire Core 15 for Palliative Care,
cs/sedatives. Difference in the associations between groups (interaction) was
better HrQoL, whereas higher symptom scores (revised Edmonton Symptom
gative association is interpreted as that higher symptom scores are associated
352 Vol. 60 No. 2 August 2020Ekstr€om et al.screening test, which might not detect more subtle
cognitive impairment and made it difficult to further
stratify the participants in different stages of cognitive
impairment. However, this present short version of the
MMSE has shown very high agreement with the full-
length version; it had 96% sensitivity and 91% specificity
to identify cognitive impairment defined as <24 points
on the full-length MMSE.27 A further support for using
this short version was that the prevalence of cognitive
impaired in the present study (17%) was similar to pre-
vious studies on cognitive impairment in patients with
cancer (15%e25%).40,41 Nonetheless, to provide a
more robust measure of cognitive status, we ran a sensi-
tivity analysis requiring the cognitive status to remain sta-
ble from baseline to the follow-up visit (either
cognitively impaired at both visits or cognitively unim-
paired at both visits), which yielded similar results. As
inability to comply with the study for reasons including
severe cognitive impairment was an exclusion criterion
(as in most trials), the present findings pertain to
mild-to-moderate cognitive impairment. Another
possible limitation includes the concurrent validity anal-
ysis using self-rated HrQoL. In a scenario, where the
cognitively impaired participants do not remember
recent symptoms (scores falsely low) and overrate their
HrQoL, the association would incorrectly be similar to
the cognitively unimpaired group. However, previous
studies support the validity and hence the use of self-
rated HrQoL scales also in cognitively impaired partici-
pants,42,43 although it has been questioned in advanced
dementia.44 Nonetheless, we acknowledge that future
studies should also include observational-based ratings
for the concurrent validity analyses. Finally, there were
more missing data for symptom ratings at follow-up
for cognitively impaired participants (about 32% vs.
about 23% for cognitively intact; Appendix Table 2).
This may have caused a slight survival bias, and it also
identifies a shortcoming of self-reported measures in
people who are cognitively impaired compared with
third-party observational assessments.
The present findings have important implications as
they support the use of self-reported symptom
measures also in patients with advanced cancer and
mild-to-moderate cognitive impairment but also high-
light that staff-assessed measures might be necessary to
avoid under-reporting of symptoms as many patients
with cancer may not be able to self-report using
questionnaires.36 This informs on the use of self-
ratings in this population both in clinical practice
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Vol. 60 No. 2 August 2020 354.e1Cognition and Symptom Rating in Cancer OutpatientsAppendixAppendix Fig. 1. Distribution of scores from the short version of MMSE at baseline stratified by the presence of cognitive
impairment. The total score was 8 p (0e1 p for date, 0e1 p for year, 0e1 p for pentagon copying, and 0e5 for spelling
WORLD backward). MMSE ¼ Mini-Mental State Examination.
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49 (8.3) 525 (89.2) 15 (2.5)
With cognitive
impairment
30 (34.9) 53 (61.3) 3 (3.5)
Cognitive impairment was defined according to the four-item short version of
Mini-Mental State Examination, where 0 p on present year or <3 p on
spelling WORLD backward or 0 p on pentagon copying was classified as
cognitive impairment.
Appendix Table 2







Pain 32.0 22.5 0.006
Tiredness 32.0 22.2 0.005
Drowsiness 32.0 22.9 0.009
Nausea 32.6 22.5 0.004
Appetite 31.5 22.2 0.007
Breathlessness 32.0 22.6 0.007
Depression 32.0 22.5 0.006
Anxiety 31.5 22.5 0.010
Well-being 32.0 23.1 0.011
P-values were analyzed using Chi-squared tests.
Appendix Table 3
Sensitivity Analysis of Symptom Scores in Patients With
and Without Cognitive Impairment Both at Baseline and











(n ¼ 589) P
Pain 1.88 (2.30) 1.87 (2.22) 0.97
Tiredness 4.37 (3.40) 3.67 (2.76) 0.087
Drowsiness 2.65 (2.95) 2.48 (2.61) 0.64
Nausea 0.33 (0.96) 0.96 (1.91) 0.018
Appetite 3.10 (3.39) 2.20 (2.81) 0.032
Breathlessness 0.67 (1.28) 1.39 (2.19) 0.021
Depression 3.02 (2.91) 2.06 (2.66) 0.014
Anxiety 2.58 (2.70) 2.02 (2.47) 0.12
Well-being 3.15 (2.41) 2.99 (2.57) 0.66
Data presented as mean (SD). P-values were calculated using t-tests.
Appendix Table 4
Sensitivity Analysis of Reliability of the Symptom Scores
in Patients With and Without Cognitive Impairment Both











Pain 0.71 (0.56e0.82) 0.51 (0.47e0.55)
Tiredness 0.63 (0.46e0.77) 0.53 (0.49e0.57)
Drowsiness 0.53 (0.36e0.70) 0.50 (0.46e0.54)
Nausea N/A 0.40 (0.36e0.44)
Appetite 0.68 (0.52e0.81) 0.49 (0.45e0.54)
Breathlessness 0.58 (0.41e0.73) 0.59 (0.55e0.63)
Depression 0.51 (0.33e0.68) 0.58 (0.54e0.62)
Anxiety 0.50 (0.33e0.67) 0.55 (0.51e0.59)
Well-being 0.59 (0.43e0.74) 0.51 (0.47e0.55)
ICC ¼ intraclass correlation coefficient; N/A ¼ not available.
Sensitivity analysis performed in patients with cognitive impairment both at
baseline and follow-up (n ¼ 52) and patients without cognitive impairment
at any of these assessments (n ¼ 589). Nausea in cognitively impaired could
not be analyzed because of few cases.
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